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Abstract 
A cDNA encoding a functional bovine, tricyclic antidepressant-sensitive noradrenaline transporter has been identified by screening a Agtl 1 cDNA 
library of the bovine adrenal medulla using the cDNA of the human noradrenaline transporter [1991, Nature 350, 350-3541. The sequence predicts 
a protein of 615 amino acids (M, 68 900). The bovine transporter shares 93% amino acid identity with the human sequence, but displays two more 
consensus sites for phosphorylation by protein kinase C. Transient expression of the transporter in COS-7 cells resulted in a sodium- and 
chloride-dependent uptake of noradrenaline with a pharmacology typical for a neuronal noradrenaline transporter. 
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1. Introduction 2. Materials and methods 
Inactivation of the neurotransmitter noradrenaline 
(NA) after its release into the synaptic cleft occurs by 
reuptake into noradrenergic nerve endings. The respon- 
sible transport system located in the plasma membrane 
is inhibited by cocaine and tricyclic antidepressants (e.g. 
desipramine), and transport of noradrenaline by the 
transporter as well as binding of desipramine to the 
transporter is absolutely dependent on sodium and chlo- 
ride ions [l-3]). Bovine adrenal medullary cells which 
share a common embryological origin with noradrener- 
gic neurons have also been shown to express this trans- 
port system [4,5]. Recently the cDNA of the human NA 
transporter has been cloned [6]. Subsequently the 
cDNAs of several other members of this family of so- 
dium- and chloride-dependent neurotransmitter trans- 
porters have been cloned [7,8], e.g. for dopamine [9-l 11, 
serotonin [12-141 or glycine [l&16]. These proteins are 
polypeptides of -600 amino acids, characterized by the 
presence within their sequence of 12 hydrophobic, puta- 
tive transmembrane domains and a large extracellular 
loop with 2-4 consensus sites for asparagine N-linked 
glycosylation [7,8]. However, while for most members of 
this family of neurotransmitter transporters sequences for at 
least two species (human and rat or bovine) are known, 
no information is available about a complete cDNA se- 
quence of a NA transporter other than the human. In 
this paper, we report the cloning, expression and phar- 
macological characterization of an antidepressant-sensi- 
tive NA transporter from bovine adrenal medulla. 
2.1. Drugs and chemicals 
If not stated otherwise, enzymes used in recombinant DNA manipu- 
lations were from Boehringer Mannheim. The enantiomers of oxap- 
rotiline were gifts from Ciba-Geigy; all other drugs and chemicals were 
from Sigma or RBYBiotrend. Tritiated noradrenaline and 35S-labelled 
nucleotides were obtained from NEN DuPont. The cDNA of the 
human noradrenaline transporter was a generous gift from Dr. Susan 
Amara [6]. 
2.2. Library screening 
A bovine adrenal medulla cDNA library (Clontech) containing about 
1.3 x lo6 independent clones with an insert range of 0.63.8 kb (within 
the EcoRI site of igt 1 l), was screened by means of a labelled cDNA 
probe of the human NA transporter (see below). The diluted library was 
used to infect the bacterial host strain, E. coli Y 1090 and was plated 
on 150 mm LB top-agar plates to a density of about 10,000 pfu/plate. 
Plates were incubated at 32°C for 12 h and thereafter chilled to 4”C, 
and plaques were transferred to nylon membranes (Hybond N+; Amer- 
sham). After denaturation, the DNA was fixed to the membranes by 
UV-crosslinking. Prehybridization and hybridization was performed 
according to the manufactor’s protocol (‘Dig luminescent labelling and 
detection kit’; Boehringer Mannheim). As a probe we used the cDNA 
of the human NA transporter [6], labelled with Dig 1 l-dUTP by ran- 
dom priming. Hybridization was performed overnight at 42°C in a 
solution containig 50% formamide. The following washes were carried 
out under low stringency conditions (2 x 5 min at 25°C with 2 x SSCI 
0.1% SDS. 2 x 15 min at 56°C with 0.1 x SSCM). 1% SDS). Hybridizing 
clones were identified by means of an anti-digoxigenin antibody conju- 
gated to alkaline phosphatase, and the chemoluminescent substrate 
AMPPD followed by autoradiography (Kodak XAR-5). 
2.3. Subcloning 
*Corresponding author. Fax: (49) (228) 735404. 
Positive phage clones were used to infect host bacteria (E. coli Y 
1090) in liquid culture. Lambda gt 11 DNA containing the inserts of 
interest was purified according to standard methods [17]. Purified DNA 
from the isolated clones was digested with the restriction enzyme EcoRI 
(20 U/pg DNA) and the released inserts were separated on 0.8% agarose 
gels. To assure that insert DNA was related to human NA transporter, 
Southern Blots were carried out according to standard protocols [17]. 
Insert DNA was isolated from agarose gels using DEAE-cellulose (NA- 
45; Schleicher & Schiill), and then ligated into the EcoRI site of the 
vector pUCl9 (Boehringer Mannheim) for sequencing, or inserts were 
236 B. Lingen et al. IFEBS Letters 342 (1994) 235-238 
ligated into the EcoRI site of the eucaryotic expression vector pSG5 
(Stratagene), for transfection and expression. After transformation of 
competent ,?Z coli DH5a (Gibco BRL), insert-containing clones were 
identified by restriction analysis and electrophoresis. pUC19 containing 
a 3.4 kb insert was digested with PstI (10 U&g DNA). Resulting 
fragments were separated by electrophoresis on 0.9% agarose gels. Two 
fragments (1.3 kb and 1.4 kb) were isolated and subcloned into the 
&I-digested pUC19. The pUC19 containing the residual 0.7 kb of the 
insert was also isolated and re-ligated. Thus, we obtained three sub- 
clones (with inserts of 0.7, 1.3 and 1.4 kb) in pUC19 for sequencing. 
After transformation of competent E. coli DHSa, large scale plasmid 
preparations were carried out, using ‘tip 2500’ columns (Quiagen) and 
the distributor’s protocol. 
2.4. Sequencing 
Sequencing was performed using the Sanger dideoxy-chain-termina- 
tion-method [18]. Single stranded templates were generated by PCR 
amplification (1 min at 94°C 1 min at 55°C 3 min at 72°C for 35 
cycles) of insert DNA (subcloned in pUCl9), using one biotinylated 
and one non-biotinylated primer (primer set B MWG-Biotech; specific 
for pUC19). Complementary strands were separatzed by means of the 
‘Dynabeads M-280 Streptavidin magnetic system’ (Dynal), according 
to the supplier’s instructions. Single stranded templates (for both direc- 
tions) were sequenced with a ‘Sequenase DNA Sequencing Kit’ (version 
2.0, USB), and in the presence of 1 U Taq DNA polymerase (Promega, 
sequencing rade) in the termination reaction. Probes were separated 
on denaturating (7 M urea) 8% acrylamide gels in a BRL (model SA) 
electrophoresis unit. After fixation and drying of the gels, autoradiogra- 
phy was performed overnight. Sequence analysis and comparisons were 
carried out by means of the computer software PC-GENE (Intelli- 
Genetics). 
2.5. Transfection and [3H]noradrenaline uptake experiments 
COS-7 cells were plated on 12-well tissue culture plates (Falcon) and 
grown at 37°C (5% CO,-incubator) in Dulbecco’s modified Eagle’s 
medium (DMEM; containing 10% fetal calf serum) to about 30% con- 
fluence before transfection. Transfections were performed according to 
standard protocols using the calcium phophate method [17]. After 
dropwise addition of 600 ~1 transfection mixture (10 fig supercoiled 
plasmid DNA, 125 mM CaCl,, 1 x BES buffer, pH 7.0) to 2 ml culture 
medium (per well), cells were incubated for 24 h at 37°C. Thereafter 
the medium was removed and cells were washed once with phosphate- 
buffered saline (PBS), incubated for 1.5 min with 15% glycerol in PBS, 
and after two washes with PBS, cells were incubated for further 24 h 
in normal culture medium. 
Uptake experiments were carried out essentially as described earlier 
[l]. Two days after transfection, the culture medium was replaced by 
3 ml of uptake buffer of the following composition: 125 mM NaCl, 
2.4 mM K,SO,, 1.2 mM KH,PO,, 1.2 mM MgSO,, 25 mM HEPES/ 
Tris, pH 7.4, 5.6 mM b-(+)glucose, 1 mM ascorbic acid, 10 ,uM par- 
gyline (to inhibit monoamine oxidase), 10 PM U-0521 (3,4-dihydroxy- 
2-methylpropiophenone, to inhibit catechol-O-methyltransferase). 
Cells were pre-incubated for 15 min (at 37°C) in the absence (control) 
or presence of the drug under study (see section 3) and then incubated 
for 10 min (if not stated otherwise) in the additional presence of 10 nM 
[‘Hlnoradrenaline. To determine the Na+- and Cl--dependence of nor- 
adrenaline transport, NaCl was replaced by LiCl or sodium acetate, 
respectively. At the end of the experiment, cells were rinsed three times 
with ice-cold uptake buffer and then solubilized in 1.5 ml 0.1% Triton 
X-100. Radioactivity of the solubilized cells was determined by scintil- 
lation counting. Speci8c uptake was defined as the difference between 
total uptake and the uptake in the presence of 10 PM nisoxetine. 
Uptake data were related to cell protein [19]. Experiments were carried 
out in duplicates and are presented as means+S.E.M. of at least three 
independent experiments; I&-values were determined using a commer- 
cial software program (GRAPHPAD INPLOT). 
3. Results and discussion 
Screening of a bovine adrenal medulla cDNA library 
(in Rgtll) with DIG-labelled cDNA of the human NA 
transporter resulted in isolation of three positive clones 
with insert sizes of 1.2, 1.6 and 3.4 kb. The largest one 
was used for all further experiments. To ascertain 
whether this insert contains a full length cDNA of the 
bovine NA transporter, it was isolated by EcoRI diges- 
tion and cloned into the eukaryotic expression vector 
pSG5. Transfection of COS-7 cells with the vector con- 
taining the insert in the correct orientation resulted in 
uptake of tritiated NA which was inhibited by the selec- 
tive NA uptake inhibitor nisoxetine, whereas no uptake 
was seen in cells transfected with the vector pSG.5 con- 
taining no insert (see Fig. 2). 
Sequence analysis revealed an open reading frame of 
1845 nucleotides encoding a 615 amino acid protein 
(M, 68,900), flanked by 10 bp of 5’- and 1,328 bp of 
3’untranslated sequence (Fig. 1); no polyadenylation 
signals were found in the 3’-noncoding sequence. The 
methionine tentatively assigned as the start of translation 
was chosen on the basis that it resembled the sequence 
around the start codon of the human noradrenaline 
transporter cDNA [6]. Hydropathicity analysis (not 
shown) of the deduced amino acid sequence suggests that 
this protein comprises 12 stretches of 19-25 amino acids 
(underlined in Fig. 1) that may represent ransmembrane 
domains (TMs). The lack of an identifiable signal se- 
quence implies that the N-terminus is located on the 
cytoplasmic side of the plasma membrane. The sequence 
also indicates the presence of three potential N-glycosyl- 
ation sites within a large, putative extracellular loop be- 
tween TM3 and TM4 (Fig. 1). Thus, the features of the 
protein sequence match very well with those of other 
members of the family of Na’- and Cl--dependent neuro- 
transmitter transporters such as the human NA trans- 
porter. 
To confirm the identity of this presumed bovine NA 
transporter, COS-7 cells were transiently transfected 
using the 3.4 kb cDNA clone ligated into pSG5. Expres- 
sion of the cDNA resulted in an uptake of tritiated NA 
(10 nM) which linearly increased with time (up to about 
15 min; data not shown). As shown in Fig. 2, 10 min 
uptake of [3H]NA (at 10 nM) was almost completely 
inhibited by the selective NA uptake inhibitor nisoxetine 
[20,21]. Furthermore, [3H]NA uptake was dependent on 
sodium and chloride since in the absence of either so- 
dium (replaced by lithium) or chloride (replaced by ace- 
tate) uptake of [3H]NA was reduced to the same low level 
as in the presence of nisoxetine (Fig. 2). The component 
of uptake not affected by nisoxetine or the absence of 
either sodium or chloride obviously represents non- 
specific, diffusional uptake of NA, since a similar low 
uptake was observed in cells transfected with the vector 
containing no insert. The sodium- and chloride-depend- 
ence of the transport system expressed in transfected 
COS-7 is typical for a neuronal NA transporter [1,3]; a 
chloride-dependence has hitherto not yet been shown for 
a cloned NA transporter. A Km of about 200 nM for NA 
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Fig. 1. Amino acid sequence of the bovine noradrenaline transporter 
eDNA (a), and nucleotides of the 5’ and 3’ noncoding sequence (b). In 
part (a), putative transm~brane domains are doubly underlined, cir- 
cles indicate potential sites for N-glycosylation, asterisks indicate po- 
tential sites for protein kinase C phosphorylation on putative intracel- 
lular domains; amino acids which differ from those of the human 
noradrenaline transporter are presented in bold-face italic letters. 
uptake (estimated from the K&, value shown in Table 1) 
is also typical for a neuronal NA transporter. Table 1 
shows the ability of transported substrates and uptake 
inhibitors to compete for the uptake of [3H]NA by trans- 
fected COS-7 cells. The selective NA uptake inhibitors 
nisoxetine and (+)oxaprotiline as well as the tricyclic 
antidepressant desipramine were the most potent compe- 
titors of uptake, whereas the antidepressant imipramine, 
which is a potent inhibitor of serotonin uptake, showed 
intermediate potency. As expected from the literature 
[22] but not yet shown in a cloned NA-transposer, the 
enantiomers of oxaprotiline exhibited pronounced stere- 
oselectivity, with (+)oxaprotiline being about 1 ,OOO-fold 
more potent than (-)oxaprotiline in inhibiting NA up- 
take. In accordance with previous findings [3], dopamine 
appears to be a substrate at least as good as noradre- 
naline, since it inhibited i3HjNA uptake with even higher 
potency as unlabelled NA (Table 1). The pharmacologi- 
cal profile of the uptake of NA by transfected COS-7 
cells confirms the identity of this protein as a neuronal 
NA transporter. 
An alignment of the amino acid sequence of this bo- 
vine NA transporter with the sequence of the human NA 
transporter reveals a very high degree of amino acid 
conservation (Fig. 1). Although the N-terminal segment 
is by two amino acids shorter than that of the human 
transporter, the bovine NA transporter is 93.5% identi- 
cal with the human NA transporter. The differences are 
largely restricted to the amino and carboxy termini, 
where 15 out of 40 differences occur. Within the bovine 
NA transporter transmembrane domains, only domains 
4, 5, 7, 8, 9 and 12 exhibit multiple amino acid substitu- 
tions relative to the human transporter. In comparisons 
with other members of the Na”/Cl- cotransporter gene 
family, the bovine NA transporter is most closely related 
to the bovine, human and rat dopamine transporters 
(about 65% homology). As in the human NA transporter 
sequence, a motif resembling a leucine zipper (amino 
A: controls 
B: no insert 
C: +lOuM nisaxetine 
D: Na+-f ree 
E: W-free 
A B C D E 
Fig. 2. Uptake of 13H]noradrenaline ([‘H]NA) in transfected COS-7 
cells. Cells were transfected with either the non-modified vector @SGS; 
B) or with a pSGS vector containing the cDNA of the bovine NA 
transporter (pSG5bNAT; A, C-E); 48 h thereafter cells were incubated 
for 10 min with 10 nM [3H]NA (A), and in the presence of 10 JLM 
nisoxetine (C) or in the absence of either Na’ (D) or Cl- (E), as de- 
scribed in Section 2. Uptake of [QNA under control conditions (A) 
was 2,836 ?z 737 fmoilmg protein. Shown are mean values ? S.E.M. of 
3-7 experiments. 
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Table 1 
Pharmacology of noradrenaline uptake in CO!+7 cells transfected with 
the bovine noradrenaline transporter cDNA 
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Compound IC,, f S.E.M. (nM) 
Desipramine 1.2 f 0.3 
(+)Oxaprotiline 1.3 f 0.3 
Nisoxetine 1.7 + 0.4 
Imipramine 48 f 22 
Dopamine 142 f 44 
(-)Noradrenaline 216 f 49 
(-)Oxaprotiline 1,409 + 785 
COS-7 cells were transiently transfected with the bovine noradrenaline 
transporter cDNA (in pSG5) as described in section 2. Uptake of 
[3H]noradrenaline (10 nM, 10 min) was measured in the absence (con- 
trols) and presence of various concentrations of the listed compounds. 
Because of the low concentration of [‘H]NA used, R&values mirror 
&-values. Hill coefficients obtained for these data did not deviate signif- 
icantly from unity. Shown are means f S.E.M. of 335 experiments. 
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